N 5 (196) 2025. P. 56–60

CHANGES OF PROTEIN EXPRESSION OF PLATINUM RESISTANCE INDICATORS UNDER THE INFLUENCE OF HYPERTHERMIA DURING THE HIPEC PROCEDURE IN RECURRENT OVARIAN CANCER

N. M. Rozhkovska, S. H. Chetverikov, M. S. Chetverikov, V. V. Chetverikova-Ovchynnyk

Odesa National Medical University, Odesa, Ukraine

DOI 10.32782/2226-2008-2025-5-9

Introduction. Ovarian cancer relapse and death are usually caused by acquired drug resistance. The mechanisms of platinum resistance are multifactorial. Excision repair cross-complementation group 1 (ERCC1) is a protein critical in removing platinum-induced DNA lesions. Microsatellite Instability (MSI) is present in a substantial proportion of ovarian cancers but knowledge about its clinical value is limited. Hyperthermia, one more promising treatment agent, delays the repair of DNA damage. Hyperthermic intraperitoneal chemoperfusion (HIPEC), which has been actively studied in recent years as a possible addition to therapy for advanced stages of epithelial ovarian cancer.

Material and methods. The study was retrospective, it included a total of 16 patients with stage IIIC epithelial ovarian cancer. For various reasons, these patients underwent suboptimal cytoreductive surgery with HIPEC + Second-look surgery with complete / optimal cytoreduction (6 patients) or relaparotomy with biopsy of residual disease due to surgical complications in 2–4 weeks interval. Immunohistochemical investigation of ERCC1 and MLH-1 expression were performed for the histological samples obtained from pre- and post HIPEC metastatic tumor tissue on the first and second surgical interventions.

Conclusions. DNA repair pathways are one of the most important factors of platinum drug resistance formation. Hyperthermia during HIPEC procedure leads to decrease in the efficiency of DNA repair pathways by reducing the expression of ERCC1 and MMR proteins. These changes may determine the proven effectiveness of HIPEC procedure with cytoreduction after NACT (which may lead to secondary platinum drug resistance formation) by overcoming platinum resistance.

Keywords: recurrent ovarian cancer, platinum resistance, HIPEC, ERCC1, MLH-1.

REFERENCES

  1. Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review). Oncol Rep. 2022 Apr;47(4):82. https://doi.org/10.3892/or.2022.8293.
  2. Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It. Medicina (Kaunas). 2023 Mar 10; 59(3):544. https://doi.org/10.3390/medicina59030544.
  3. Atallah GA, Kampan NC, Chew KT, et al. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers. Int J Mol Sci. 2023 Jan 19;24(3):1973. https://doi.org/10.3390/ijms24031973.
  4. Guffanti F, Alvisi MF, Caiola E, et al. Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. Cancers (Basel). 2020 Aug 24;12(9):2398. https://doi.org/10.3390/ cancers12092398. PMID: 32847049.
  5. Liblab S, Vusuratana A, Areepium N. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy. Asian Pac J Cancer Prev. 2020 Jul 1;21(7):1925-1929. https://doi.org/10.31557/APJCP.2020.21.7.1925. PMID: 32711417.
  6. Fraune C, Rosebrock J, Simon R et al. High homogeneity of MMR deficiency in ovarian cancer. Gynecol Oncol. 2020 Mar; 156(3): 669-675. https://doi.org/10.1016/j.ygyno.2019.12.031.
  7. Mitric C, Salman L, Abrahamyan L, et al. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2023 Mar;170:133-142. https://doi.org/10.1016/ j.ygyno.2022.12.008. Epub 2023 Jan 20. PMID: 36682091.
  8. Atwal A, Snowsill T, Dandy MC, et al. The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis. Int J Cancer. 2022 Nov 1;151(9):1626-1639. https://doi.org/10.1002/ijc.34165. Epub 2022 Jul 6. PMID: 35792468; PMCID: PMC9539584.
  9. da Costa A, Valadares CV, Baiocchi G, et al. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Ann Surg Oncol 2015; 971–978. https://doi.org/10.1245/ s10434-015-4623-z
  10. Xiao Y, Xie S, Zhang N, et al. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis. Gynecol Obstet Invest. 2018;83(3):209-219. https://doi.org/10.1159/000485618. Epub 2017 Dec 21. PMID: 29402804.
  11. Marchocki Z, Tone A, Virtanen C, et al. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. Journal of Ovarian Research. 2022; 15(1): 50. https://doi.org/10.1186/s13048-022-00983-5
  12. Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA. 2011 Jun 14;108(24):9851-6. https://doi.org/10.1073/pnas.1101053108. Epub 2011 May 9. PMID: 21555554; PMCID: PMC3116433.
  13. Batista TP, Dal Molin GZ. Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer? Cancer Drug Resist. 2020 Jul 10;3(3):666-671. https://doi.org/10.20517/cdr.2020.27. PMID: 35582446; PMCID: PMC8992489.
  14. Schaaf L, Schwab M, Ulmer C, et al. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Res. 2016 May 15;76(10):2868-75. https://doi.org/10.1158/0008-5472.CAN-15-2908. Epub 2016 Mar 24. PMID: 27013194.
  15. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240. https://doi.org/10.1056/NEJMoa1708618. PMID: 29342393.
  16. Hulshof EC, Lim L, de Hingh IHJT, Gelderblom H, Guchelaar HJ, Deenen MJ. Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. Front Pharmacol. 2020 Oct 6;11:577968. https://doi.org/10.3389/fphar.2020.577968. PMID: 33117169; PMCID: PMC7575928.
  17. Tonello M, Baratti D, Sammartino P, et al. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2022 Jun;29(6):3405-3417. https://doi.org/10.1245/s10434-021-11045-3.
  18. Hamed AB, Shuai Y, Derby J et al. Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases. Ann Surg Oncol. 2023 Jul;30(7):4459-4470. https://doi.org/10.1245/s10434-023-13463-x. PMID: 37085655.
  19. Massalou D, Benizri E, Chevallier A et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017 Feb;213(2):377-387. https://doi.org/10.1016/j.amjsurg.2016.03.008. Epub 2016 Aug 5. PMID: 27816197.
  20. Larsen SG, Goscinski MA, Dueland S et al. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. Br J Cancer. 2022 Mar;126(5):726-735. https://doi.org/10.1038/s41416-021-01620-6.
View article PDF